Fully Human Anti-ACVR2A Antibodies
This poster details the discovery and validation of fully human anti-ACVR2A antibodies for metabolic and musculoskeletal disorders . Overcoming high species homology via a specialized transgenic platform, it provides comprehensive data on pathway blockade, pharmacokinetics, and in vivo efficacy for improving body composition and muscle function.
内容速递 This research presents the successful generation of fully human anti-ACVR2A antibodies—specifically A0009 and A0040—using the HUGO-Ab-eKO platform. Preclinical findings demonstrate these candidates possess sub-nanomolar affinity, superior pharmacokinetics, and distinct selectivity for ACVR2A . The study highlights their robust in vivo efficacy in reducing fat mass while enhancing muscle grip strength, validating their therapeutic potential for metabolic and muscle-wasting conditions.
核心要点 - Innovative Discovery: Utilizes the HUGO-Ab-eKO transgenic mouse platform to overcome >99% sequence homology, generating fully human antibodies.
- Enhanced Selectivity: Surface Plasmon Resonance (SPR) confirms sub-nanomolar binding affinity and superior selectivity for ACVR2A over ACVR2B.
- Potent Pathway Blockade: Reporter gene assays demonstrate dose-dependent inhibition of both ACVR2A-ALK4 and ACVR2A-ALK7 signaling pathways.
- Superior Pharmacokinetics: Lead candidates exhibit significantly extended half-lives and higher systemic exposure (AUC) in wild-type murine models.
- Dual Functional Benefits: Demonstrates robust in vivo efficacy by reducing fat mass in DIO mice and improving grip strength in SCID models.
如果您对《Fully Human Anti-ACVR2A Antibodies》感兴趣，欢迎填写信息免费领取
